The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum
Latest Information Update: 20 Sep 2022
At a glance
- Drugs Sucroferric oxyhydroxide (Primary)
- Indications Hyperphosphataemia
- Focus Therapeutic Use
- 15 Sep 2022 Results of a secondary analysis assessed the effect of the phosphate binder sucroferric oxyhydroxide in dialysis patients on endogenous calciprotein particles, inflammation, and vascular cells published in the Nephrology Dialysis Transplantation
- 19 Jul 2019 Status changed from active, no longer recruiting to completed.
- 07 Jan 2019 Status changed from recruiting to active, no longer recruiting.